COMPASS Pathways plc (CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is listed on the NASDAQ exchange under the ticker symbol "CMPS".
Founded in 2016 and located in London, UK, COMPASS Pathways is at the forefront of medical and scientific research with a vision to create a world of mental wellbeing. They are pioneering the development of a new model of mental health care to transform lives and also the health care system. The company aims to enhance and deliver better treatments that will make a significant difference for patients and their families affected by mental health complications.
COMPASS Pathways has made a remarkable leap into a new kind of therapy by researching and developing psilocybin therapy, a form of psychedelic treatment. Psilocybin is a naturally occurring psychedelic compound found in certain types of mushrooms. They are studying this new approach to therapy by developing what could be the first regulatory-approved, prescription treatment for patients with treatment-resistant depression.
In 2019, COMPASS received Breakthrough Therapy designation from the FDA for its psilocybin therapy for treatment-resistant depression. This status will help to accelerate the development and review process and is only granted to drugs that show significant treatment advantages over existing options.
The therapy developed by COMPASS, known as COMP360, is a synthesized psilocybin, precisely dosed and combined with psychological support from a specially trained therapist. The therapy is used in controlled settings to help provide a safe and potentially transformative patient experience.
Through harnessing the therapeutic potential of psilocybin, COMPASS Pathways represents an innovative approach to psychiatric treatment. This could make significant strides in the treatment of major depressive disorder, a condition affecting millions worldwide, revolutionising patient care and potentially shaking up mental healthcare for good.
They are committed to conducting high-quality, rigorously controlled clinical trials to provide evidence to medical, regulatory and ethical review boards, paving the way for future mental health treatments.
As a company, COMPASS Pathways continues to make significant strides within their field, symbolising a hope for future developments in mental health care and posing the potential for novel strategies in care and treatment.